<div class="container">

<table style="width: 100%;"><tr>
<td>bootstrap_f2</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Bootstrap f2</h2>

<h3>Description</h3>

<p>The function <code>bootstrap_f2()</code> generates <code>rr</code> bootstrap replicates
of the similarity factor <code class="reqn">f_2</code> based on resampling of complete profiles
(nonparametric bootstrap) or on resampling per time point the values
between profiles (parametric bootstrap). Estimates of “normal”,
“basic”, “student”, “percent” and of
“bias-corrected, accelerated” (BCa) percentile intervals are returned.
</p>


<h3>Usage</h3>

<pre><code class="language-R">bootstrap_f2(
  data,
  tcol,
  grouping,
  rand_mode = "complete",
  rr = 999,
  each = 12,
  new_seed = 100,
  confid = 0.9,
  use_ema = "no",
  bounds = c(1, 85),
  nsf = c(1, 2),
  ...
)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>data</code></td>
<td>
<p>A data frame with the dissolution profile data in wide format.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>tcol</code></td>
<td>
<p>A vector of indices that specifies the columns in <code>data</code>
that contain the % release values. The length of <code>tcol</code> must be
three or longer.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>grouping</code></td>
<td>
<p>A character string that specifies the column in <code>data</code>
that contains the group names (i.e. a factorial variable, e.g., for the
differentiation of batches or formulations of a drug product).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>rand_mode</code></td>
<td>
<p>A character string that indicates whether complete profiles
shall be randomised (<code>"complete"</code>, the default) or individual data
points (<code>"individual"</code>).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>rr</code></td>
<td>
<p>An integer that specifies the number of bootstrap replicates. The
default is <code>999</code>.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>each</code></td>
<td>
<p>An integer that specifies the number of dissolution profiles to
be selected per group per randomisation round. The default is <code>12</code>.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>new_seed</code></td>
<td>
<p>An integer for setting the seed for random number generation.
The default is <code>100</code>.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>confid</code></td>
<td>
<p>A numeric value between 0 and 1 that specifies the confidence
limit for the calculation of the bootstrap confidence intervals. The
default is <code>0.9</code>.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>use_ema</code></td>
<td>
<p>A character string that indicates whether the similarity
factor <code class="reqn">f_2</code> should be calculated according to the EMA guideline
“On the investigation of bioequivalence” (<code>"yes"</code>) or not
(<code>"no"</code>, the default). The default is <code>"no"</code> because the
bootstrap <code class="reqn">f_2</code> method is one of the possible solutions if the
condition concerning the variability between the profiles does not allow
the evaluation of <code class="reqn">f_2</code> according to the EMA guideline. A third option
is <code>"ignore"</code>. If <code>use_ema</code> is <code>"yes"</code>, the <code>bounds</code>
are <code>c(0, 85)</code> per definition. If <code>use_ema</code> is <code>"no"</code>, the
appropriate profile portion is determined on the basis of the values of
the parameter <code>bounds</code>. If <code>use_ema</code> is <code>"ignore"</code>, the
complete profiles are used as specified by the parameter <code>tcol</code>.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>bounds</code></td>
<td>
<p>A numeric vector of the form <code>c(lower, upper)</code> that
specifies the “lower” and “upper” limits, respectively, for
the % drug release given that <code>use_ema</code> is <code>"no"</code>. The default
is <code>c(1, 85)</code>. Mean % release values of any of the two groups being
compared that are smaller than or equal to the lower bound are ignored and
only the first mean % release value that is greater than or equal to the
upper bound is included while all the subsequent values are ignored. If
<code>use_ema</code> is <code>"yes"</code> the <code>bounds</code> are <code>c(0, 85)</code> per
definition. If <code>use_ema</code> is <code>"ignore"</code> the <code>bounds</code> are
disregarded.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nsf</code></td>
<td>
<p>A vector of positive integers that specify the “number
of significant figures” (nsf) of the corresponding values of the
<code>bounds</code> parameter. It must thus have the same length as the
<code>bounds</code> parameter. Before the % release values are compared with
the limits that are specified by the <code>bounds</code> parameter, they are
rounded to the corresponding number of significant figures as specified
by the <code>nsf</code> parameter.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>...</code></td>
<td>
<p>Named parameters of the functions <code>stat.fun()</code>,
<code>ran.fun()</code> and <code>boot()</code>.</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>Information on <code class="reqn">f_2</code> can be found in at least three FDA
guidances and in the guideline of the European Medicines Agency (EMA)
“On the investigation of bioequivalence” (EMA 2010). For the
assessment of the similarity of dissolution profiles using the similarity
factor <code class="reqn">f_2</code> according to the EMA guideline the following constraints
do apply:
</p>

<ol>
<li>
<p> A minimum of three time points (without zero) are necessary.
</p>
</li>
<li>
<p> The time points should be the same for the two formulations.
</p>
</li>
<li>
<p> For every time point and for each formulation at least 12 data points
are required.
</p>
</li>
<li>
<p> A maximum of one mean value per formulation may be &gt; 85% dissolved.
</p>
</li>
<li>
<p> The coefficient of variation (%CV) should be &lt; 20% for the first
time point and &lt; 10% from the second to the last time point for any
formulation.
</p>
</li>
</ol>
<p>Dissolution profiles are regarded as similar if the <code class="reqn">f_2</code> value is
between 50 and 100. <br></p>
<p>One often encountered problem is that the %CV constraint cannot be
fulfilled. One possibility in this situation is the use of the bootstrap
<code class="reqn">f_2</code> method (Shah 1998) by which the distribution of <code class="reqn">f_2</code> is
simulated to obtain an unbiased estimate of the expected value of <code class="reqn">f_2</code>
and the variability of the underlying distribution. For the <code class="reqn">f_2</code>
calculation only those parts of the profiles are taken into account where
the means (per formulation) are <code class="reqn">&gt; d</code>% dissolved (e.g., <code class="reqn">d = 1</code>)
and a maximum of one mean value per formulation is <code class="reqn">&gt; 85</code>% dissolved.
In the literature it is suggested to make use of the lower 90% bias
corrected and accelerated (BCa) confidence interval (CI) limit to come to
a decision in terms of similarity (Stevens (2015)).
</p>


<h3>Value</h3>

<p>An object of class ‘<code>bootstrap_f2</code>’ is returned,
containing the following list elements:
</p>
<table>
<tr style="vertical-align: top;">
<td><code>Boot</code></td>
<td>
<p>An object of class ‘<code>boot</code>’ with the corresponding
components.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Profile.TP</code></td>
<td>
<p>A named numeric vector of the columns in <code>data</code>
specified by <code>tcol</code> and depending on the selection of <code>use_ema</code>.
Given that the column names contain extractable numeric information, e.g.,
the testing time points of the dissolution profile, it contains the
corresponding numeric values. Elements where no numeric information could
be extracted are <code>NA</code>.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>L</code></td>
<td>
<p>A vector of the Jackknife leave-one-out-values.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CI</code></td>
<td>
<p>An object of class ‘<code>bootci</code>’ which contains the
intervals.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>BCa_CI</code></td>
<td>
<p>The lower and upper limits of the BCa interval calculated
by the <code>boot.ci()</code> function from the ‘<code>boot</code>’ package.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Shah_BCa_CI</code></td>
<td>
<p>The lower and upper limits of the BCa interval calculated
according to Shah (Shah 1998).</p>
</td>
</tr>
</table>
<h3>References</h3>

<p>United States Food and Drug Administration (FDA). Guidance for industry:
dissolution testing of immediate release solid oral dosage forms. 1997.<br><a href="https://www.fda.gov/media/70936/download">https://www.fda.gov/media/70936/download</a>
</p>
<p>United States Food and Drug Administration (FDA). Guidance for industry:
immediate release solid oral dosage form: scale-up and post-approval
changes, chemistry, manufacturing and controls, <em>in vitro</em> dissolution
testing, and <em>in vivo</em> bioequivalence documentation (SUPAC-IR). 1995.<br><a href="https://www.fda.gov/media/70949/download">https://www.fda.gov/media/70949/download</a>
</p>
<p>European Medicines Agency (EMA), Committee for Medicinal Products for
Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 2010;
<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">
CPMP/EWP/QWP/1401/98 Rev. 1</a>.
</p>
<p>Stevens, R. E., Gray, V., Dorantes, A., Gold, L., and Pham, L. Scientific
and regulatory standards for assessing product performance using the
similarity factor, <code class="reqn">f_2</code>. <em>AAPS Journal</em>. 2015; <strong>17</strong>(2):
301-306.<br><a href="https://doi.org/10.1208/s12248-015-9723-y">doi:10.1208/s12248-015-9723-y</a>
</p>
<p>Shah, V. P., Tsong, Y., Sathe, P., and Liu, J. P. <em>In vitro</em> dissolution
profile comparison - statistics and analysis of the similarity factor,
<code class="reqn">f_2</code>. <em>Pharm Res</em>. 1998; <strong>15</strong>(6): 889-896.<br><a href="https://doi.org/10.1023/A%3A1011976615750">doi:10.1023/A:1011976615750</a>
</p>


<h3>See Also</h3>

<p><code>boot</code>, <code>boot.ci</code>,
<code>mimcr</code>, <code>mztia</code>.
</p>


</div>